 The purpose of this trial is to evaluate in a Phase 2 A study, the analgesic tolerability, safety and activity of IDN 5243 3-glycosyl-3-O-demethylthiocolchicine derivative administered intramuscularly at 4mg b.i.d. for 5 days in subjects with Low Back Pain LBP. 